A new study published in the Journal of Clinical Hypertension evaluated the effectiveness of percutaneous renal revascularization (PRR) with stenting for the treatment of atherosclerotic renal artery stenosis (ARAS) in patients with coronary artery disease; and the usefulness of captopril renal scintigraphy for predicting clinical outcomes after PRR. This study included 64 consecutive patients, referred for evaluation of suspected ARAS, after coronary angiography, who underwent baseline captopril renal scintigraphy followed by renal angiography. It was noted that 68.7% of these patients were diagnosed with a significant ARAS≥60% and were treated with PRR plus medical therapy. Twenty-four months after PRR, 86.4% and 73.3% of patients showed a hypertension and renal benefit, respectively. Meanwhile, captopril renal scintigraphy positivity had moderate sensitivity and high specificity in predicting a hypertension and renal benefit. On the contrary, in patients with ARAS≥70%, the sensitivity and specificity were 100% for both hypertension and renal benefit. From the results, it was inferred that PRR for ARAS rendered a substantial benefit in patients with a high coronary artery disease burden. Hence, it was stated that captopril renal scintigraphy was highly accurate in predicting clinical outcomes.